Agomab Therapeutics director David R. Epstein buys 5,000 common shares for $44,500

Bitget2026/10/09 12:02

Agomab Therapeutics director David R Epstein bought 5,000 common shares at USD 8.90. Directly held stake rose to 15,000 common shares following the purchase. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001445826-26-000014), on October 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

UK funds significantly reduced their holdings in SpaceX last week and had fully exited Tesla as of April.

格隆汇•2026/11/09 05:55

Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF

FXStreet•2026/11/09 05:45

Sun Machinery CEO Park Kyung-hee Raises Stake to 8.40% From 8.31%

Bitget•2026/11/09 05:37

The central bank has increased its gold reserves for 24 consecutive months, with October’s increase hitting a record high for the period.

新浪财经•2026/11/09 05:37